Edward M. Kaye M.D., CEO at Stoke Therapeutics, Inc. (STOK), sold 82,036 shares at $15.39 ($1.3M) on 2024-05-20, disclosed to the SEC on 2024-05-22.
Scheduled sale ($1.3M) by CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $15.39 | 39,686 | $611K | 48.3% |
| 2 | $15.39 | 39,686 | $611K | 48.3% |
| 3 | $16.05 | 2,664 | $43K | 3.4% |
| Total | $15.41 avg | 82,036 | $1.3M | 100% |
| Filing → |
| STOK | SELL | 2025-12-10 | $702K | — | Filing → |
| STOK | SELL | 2025-12-05 | $879K | — | Filing → |
| STOK | SELL | 2025-12-03 | $65K | — | Filing → |